Drugs Made In America Acquisition (DMAAR) Total Liabilities (2024 - 2025)

Drugs Made In America Acquisition (DMAAR) posted Total Liabilities of $7.3 million for Q4 2025, down 1.09% on a QoQ basis from $7.4 million in Q3 2025, and up 814.47% year-over-year from $795669.0 in Q4 2024.

Drugs Made In America Acquisition (DMAAR) Total Liabilities (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition's Total Liabilities history runs 2 years deep, the most recent figure standing at $7.3 million for Q4 2025.

  • Quarterly Total Liabilities rose 814.47% year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (up 814.47% YoY) and the FY2025 annual result came in at $7.3 million, up 814.47% from the prior year.
  • Total Liabilities was $7.3 million for Q4 2025 at Drugs Made In America Acquisition, down from $7.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $7.4 million in Q3 2025 and bottomed at $795669.0 in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Liabilities (Qtr)
1 SIM Acquisition Corp. I 314.52 Mn 314.52 Mn - 768,221.00
2 Thayer Ventures Acquisition 208.29 Mn 208.29 Mn - 8.64 Mn
3 Newbury Street II Acquisition 185.26 Mn 185.26 Mn - 6.16 Mn
4 Dynamix 178.78 Mn 178.78 Mn - 27.35 Mn
5 Hallmark Venture 103.01 Mn 102.76 Mn - 176,636.00
6 Voyager Acquisition 99.58 Mn 99.45 Mn - 13.34 Mn
7 Gores Holdings X 95.80 Mn 95.37 Mn - 31.85 Mn
8 Archimedes Tech SPAC Partners 89.88 Mn 89.88 Mn - 8.19 Mn
9 Cohen Circle Acquisition 80.05 Mn 80.05 Mn - 10.93 Mn
10 Drugs Made In America Acquisition 1.46 Mn 1.46 Mn - 7.28 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 7.28 Mn
Sep 30, 2025 7.36 Mn
Jun 30, 2025 7.20 Mn
Mar 31, 2025 7.25 Mn
Dec 31, 2024 795,669.00